Mount Sinai Genomics, INC. (D/B/A Sema4)
enables physicians & consumers to engage the digital universe of health data.
Based in CT
AI Overview
With $100K in lobbying spend across 6 quarterly filings, Mount Sinai Genomics, INC. (D/B/A Sema4) is an active lobbying client. Their lobbying covers 1 issue area. Active from 2018 to 2019.
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2018 | $80K |
| 2019 | $20K |
Issues Lobbied
Lobbying Firms
Lobbyists
Government Agencies Targeted
These are the government entities that Mount Sinai Genomics, INC. (D/B/A Sema4) disclosed contacting in their lobbying filings.
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues
newborn screening, reimbursement of diagnostics
American Competitiveness in Biotechnology
Local Coverage Determination Clarification Act of 2018 (HR 3635/S 794)
companion diagnostics at FDA, no bill # Verifying Accurate Leading-Edge IVCT Development (VALID) Act, coverage and reimbursement of molecular diagnostics.
Related Analysis
Related Investigations
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.